Investigational drug · Phase 2
PD-L1 monoclonal antibody
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non-Small Cell Lung Cancer, Advanced Malignant Solid Tumor.
Phase 2Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
732
Any phase or sponsor naming "PD-L1 monoclonal antibody"
First trial start
2025
Dec 12, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "PD-L1 monoclonal antibody", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-Small Cell Lung Cancer
- Advanced Malignant Solid Tumor
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "PD-L1 monoclonal antibody" as an intervention, largest first.
Sungkyunkwan UniversityAcademic, hospital or other
NCT04115410 · 4,724 participants (planned) · Start Jul 1, 2020 · Primary completion Sep 23, 2021
Drug: PD-1 inhibitor; Chemotherapy Drugs, Cancer · For: Carcinoma, Non-Small-Cell Lung; Immune-Related Adverse Events
Quanli GaoGovernment (non-federal)
NCT06693440 · 3,000 participants (planned) · Start Jul 1, 2021 · Primary completion Nov 13, 2027
Drug: PD-1 Inhibitors · For: Efficacy, Team; Adverse Event
Sites: Zhengzhou, China
Johns Hopkins UniversityAcademic, hospital or other
NCT04898751 · 2,214 participants · Start Jan 1, 2008 · Primary completion Aug 31, 2020
Drug: Immune checkpoint inhibitor (ICI) · For: Cutaneous Toxicity From ICI Therapy
Sites: Baltimore, Maryland
- Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2Pivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07431281 · 2,130 participants (planned) · Start Feb 3, 2026 · Primary completion Aug 16, 2029
Drug: Sonesitatug vedotin; Rilvegostomig and 6 more · For: Gastric Cancer; Gastroesophageal Junction Adenocarcinoma; Esophageal Cancer
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 314 sites in all
SWOG Cancer Research NetworkResearch network
NCT02154490 · 1,864 participants · Start Jul 8, 2014 · Primary completion Apr 1, 2022
Drug: Docetaxel; Durvalumab and 9 more · For: Recurrent Squamous Cell Lung Carcinoma; Stage IV Squamous Cell Lung Carcinoma AJCC v7
Sites: Birmingham, Alabama; Anchorage, Alaska; Fairbanks, Alaska · 1,004 sites in all
CCTU- Cancer ThemeAcademic, hospital or other
NCT04107168 · 1,800 participants (planned) · Start Jul 8, 2020 · Primary completion Jul 8, 2024
Drug: Nivolumab; Pembrolizumab and 5 more · For: Melanoma; Renal Cancer; Lung Cancer
Sites: Bath, United Kingdom; Bournemouth, United Kingdom; Bristol, United Kingdom · 13 sites in all
- Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)Pivotal-lookingRecruiting
BioNTech SEIndustry
NCT06712316 · 1,580 participants (planned) · Start Jan 7, 2025 · Primary completion Jan 2029
Drug: Pumitamig; Pembrolizumab and 3 more · For: Non-small Cell Lung Cancer
Sites: Birmingham, Alabama; Anchorage, Alaska; Concord, California · 366 sites in all
- SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast CancerPivotal-lookingActive, not recruiting
UNICANCERAcademic, hospital or other
NCT02299999 · 1,460 participants · Start Apr 7, 2014 · Primary completion Dec 2022
Drug: AZD2014; AZD4547 and 17 more · For: Metastatic Breast Cancer
Sites: Angers, France; Avignon, France; Bordeaux, France · 25 sites in all
BioNTech SEIndustry
NCT07070232 · 1,438 participants (planned) · Start Aug 12, 2025 · Primary completion Mar 2028
Drug: BNT326; Pumitamig and 2 more · For: Advanced Solid Tumor
Sites: Phoenix, Arizona; San Francisco, California; Hartford, Connecticut · 79 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT03740165 · 1,367 participants · Start Dec 18, 2018 · Primary completion Aug 26, 2024
Drug: Pembrolizumab; Placebo for pembrolizumab and 6 more · For: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Neoplasms
Sites: Birmingham, Alabama; Tucson, Arizona; Burbank, California · 227 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Targeting the metabolic-immune regulator SLC35F6 enhances temozolomide and anti-PD-L1 therapy in glioma.
Lu P, Wang W, Lu B, et al. · Cancer Lett 2026
- Clinicopathologic significance of PD-L1 expression in clear cell renal cell carcinoma.
Onyszczuk M, Szweda-Gandor N, Rynkiewicz M, et al. · Medicine (Baltimore) 2026
- Immune Checkpoint Blockade Enhances the Abscopal Effect of [177Lu]Lu-DOTA-JR11 PRRT in an SSTR2-Heterogeneous Bilateral Tumor Model.
Cheng Z, Zhou H, Liu L, et al. · Eur J Nucl Med Mol Imaging 2026
- A systematic review and meta-analysis on survival, pathological response, and safety of durvalumab in early-stage non-small cell lung cancer.
Imran M, Naeem A, Saqib N, et al. · Clin Transl Oncol 2026
- WD-3 improves anti-PD-L1 therapy by remodeling the tumor immune microenvironment through gut microbiota.
Shi Y, Xue Q, Yuan Y, et al. · Immunobiology 2026
- Functionalized Fluorescent Nanodiamonds Reveal Therapeutic Protein Clearance Through ENDOTAC Linked to AUTOTAC.
Lin YW, Lai YH, Pang JY, et al. · Adv Healthc Mater 2026
Also in development for Non-Small Cell Lung Cancer
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.